Lilly

Drugmakers Envision Future of Obesity Treatments Beyond GLP-1s

Drugmakers are exploring new obesity treatments beyond GLP-1s, including less frequent shots and pills with fewer side effects. Eli Lilly's experimental drug retatrutide showed significant weight loss, while competitors like Novo Nordisk, Structure Therapeutics, AstraZeneca, Pfizer, and Amgen are developing new oral and injectable options. The market is expected to grow significantly, with pricing and insurance coverage being key factors.

Pharma-Investitionen: Eli Lilly und Boehringer Ingelheim reduzieren Pläne

Pharmaunternehmen Eli Lilly und Boehringer Ingelheim reduzieren geplante Investitionen in Deutschland aufgrund von Sparplänen der Bundesregierung. Ministerpräsident Schnieder versucht zu vermitteln, während die Koalition in Berlin vor einem Dilemma steht.

Pharma-Investitionen: Boehringer Ingelheim und Eli Lilly kürzen in Deutschland

Boehringer Ingelheim und Eli Lilly reduzieren ihre Investitionen in Deutschland aufgrund des angekündigten Spargesetzes von Gesundheitsministerin Nina Warken. Dies geschieht vor dem Hintergrund globaler Preisdruck-Diskussionen, insbesondere aus den USA.

Eli Lilly Halves Investment in German Plant Amid Healthcare Law Concerns

Eli Lilly is slashing its €2.3 billion investment in a German manufacturing plant by half due to proposed healthcare cost-cutting legislation. CEO Dave Ricks criticized the reforms, warning Germany could fall behind other European markets. The reduced investment will impact factory output and job creation.

Lilly's Alzey Plant: A Symbol of German Pharma Ambitions

In April 2024, Lilly CEO David Ricks, Chancellor Olaf Scholz, Minister-President Malu Dreyer, and Health Minister Karl Lauterbach attended the groundbreaking for Lilly's new plant near Alzey, Rheinland-Pfalz. Lilly plans to invest $2.5 billion, with Lauterbach noting Germany's growing attractiveness as a pharma location.

Pharma-Giganten kürzen Pläne in Rheinland-Pfalz wegen deutscher Gesundheitspolitik

Zwei große Pharmaunternehmen, Lilly und Boehringer Ingelheim, reduzieren ihre Investitionspläne in Rheinland-Pfalz. Grund sind die Gesundheitspolitik und Sparpläne der Bundesregierung, die als "schreckliches Signal" und "keine attraktiven Rahmenbedingungen" kritisiert werden.

Lilly porta la salute in piazza a Milano con 'Io prevengo'

Lilly partecipa alla 'Health week' di Milano con il camper 'Io prevengo' in Piazza Gae Aulenti dal 4 al 6 giugno, offrendo controlli cardiometabolici gratuiti e consulenze nutrizionali con testimonial sportivi.

Pharma giants Eli Lilly and Boehringer Ingelheim cut German investments

Eli Lilly and Boehringer Ingelheim are reducing planned investments in Germany, citing government austerity measures in healthcare. Eli Lilly is cutting its Alzey project by 50%, while Boehringer Ingelheim is halting €900 million in planned spending.

Boehringer Ingelheim streicht 900 Millionen Euro Investitionen in Deutschland

Boehringer Ingelheim streicht geplante Investitionen von 900 Mio. Euro in Deutschland bis 2030. Als Grund nennt das Unternehmen Sparpläne der Bundesregierung und verschlechterte Rahmenbedingungen. Eli Lilly halbiert ebenfalls Investitionen in Deutschland.

Eli Lilly und Boehringer Ingelheim reduzieren Investitionen in Deutschland

Eli Lilly reduziert seine geplanten Investitionen in eine neue Produktionsstätte in Alzey um die Hälfte und stoppt Boehringer Ingelheim geplante Ausgaben in dreistelliger Millionenhöhe. Beide Unternehmen nennen schwierige Rahmenbedingungen und Sparpläne im deutschen Gesundheitswesen als Gründe.

Eli Lilly reduziert Milliardeninvestition in Deutschland wegen Sparplänen

US-Pharmakonzern Eli Lilly reduziert geplante Milliardeninvestition in Alzey, Deutschland um 50% wegen Sparplänen der Bundesregierung. Konzernchef kritisiert Deutschland als letzten Platz bei Branchenunterstützung in Europa.

Eli Lilly streicht Milliardeninvestition in Deutschland nach Sparplänen

Eli Lilly streicht geplante Investitionen von 2,3 Mrd. Dollar in Deutschland wegen Sparplänen. Boehringer Ingelheim zieht ebenfalls Milliarden ab. Der US-Pharmakonzern kritisiert die Gesundheitsreform als "schreckliches Signal" und erwägt, keine neuen Medikamente mehr auf den deutschen Markt zu bringen.

Eli Lilly's Head of Business Development Discusses Ambitious Dealmaking Strategy

Eli Lilly, now the world's largest pharma company, is aggressively pursuing acquisitions, spending over $10 billion on eight deals this year compared to $4 billion last year. Driven by its weight loss drug success, the company is shifting from early-stage bets to more experimental, higher-priced drugs.

CVS Health to Restore Coverage of Eli Lilly's Weight Loss Drugs

CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound on Oct. 1 and add coverage of its new obesity pill Foundayo on June 1, making both GLP-1 medications co-preferred options on its standard commercial formulary, affecting 25-30 million Americans and boosting Lilly's market position against Novo Nordisk.

Eli Lilly, Üç Şirketi 3,8 Milyar Dolara Ulaşabilecek Bedelle Satın Almak İçin Anlaşma Yaptı

ABD merkezli ilaç şirketi Eli Lilly, bulaşıcı hastalıklar ve aşı alanındaki araştırmalarını genişletmek amacıyla Curevo, LimmaTech Biologics ve Vaccine Company'yi toplamda 3,8 milyar dolara ulaşabilecek bedelle satın almak üzere anlaşma yaptı.

Canetas emagrecedoras ilegais: Foz do Iguaçu se torna porta de entrada para produtos sem controle sanitário

Foz do Iguaçu se tornou o principal ponto de entrada de canetas emagrecedoras ilegais no Brasil, com produtos sem controle sanitário causando graves reações em usuários. Especialistas alertam para a falta de pureza, esterilidade e dosagem correta.

Lilly anuncia resultados de retatrutida, su fármaco para la obesidad, que lo sitúan como el más potente

Lilly presenta resultados preliminares de retatrutida, un triple agonista GIP/GLP-1/glucagón, mostrando la mayor pérdida de peso hasta la fecha en obesidad. El fármaco también mejora factores de riesgo cardiovascular.

Eli Lilly's Retatrutide Achieves Significant Weight Loss in Late-Stage Trial

Eli Lilly's new obesity drug, retatrutide, showed significant weight loss in a late-stage trial, with the highest dose leading to an average loss of 28.3% over 80 weeks. The drug targets three gut hormones and appears more effective than existing treatments, bringing Lilly closer to regulatory approval.

Trump-Investitionen: Aktienkauf vor politischen Entscheidungen wirft Schatten

US-Präsident Donald Trumps Investmentfirma kaufte Aktien von Eli Lilly, Apple und Nvidia kurz vor politischen Entscheidungen, die diesen Unternehmen Vorteile brachten, was zu Anschuldigungen von Interessenkonflikten führt.

Markets Lower on Inflation Fears; Eli Lilly, Google AI Updates

US markets edged lower Tuesday amid rising inflation fears driven by high energy prices and interest rate hikes. Eli Lilly saw gains on positive GLP-1 drug survey data, while Google unveiled AI advancements at its I/O conference.

Donald Trump's Investments in Eli Lilly Amidst Obesity Drug Access Expansion

Financial disclosures reveal hundreds of thousands of dollars invested in Eli Lilly on Donald Trump's behalf in early 2026, coinciding with his administration's initiatives to expand access to obesity treatments like those produced by Lilly.

Eli Lilly Focuses on Alzheimer's Innovation, Launches Lormalzi in India

Eli Lilly prioritizes Alzheimer's in its innovation pipeline, launching Lormalzi (donanemab), a monthly amyloid-targeting therapy for early Alzheimer's, priced at ₹91,688 per vial in India.

Eli Lilly halts India obesity awareness campaign

Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly's dominance

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.